CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Calcium Hydroxyapatitedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05885035
NCT05885035Phase 1Completed
CompareCT.gov

Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks

Kalpna Kay Durairaj, MD, FACS·interventional·Posted Jun 1, 2023·Updated Jul 17, 2023

In Brief

A Phase 1 clinical trial evaluating Calcium Hydroxyapatite for Cellulite. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to test the efficacy of Calcium Hydroxylapatite (CaHA) in treating cellulite dimples in the buttocks. Participants will: * have 3 treatment sessions at weeks 0, 4, and 8 and a final live assessment visit at week 14 * receive approximately 2 syringes per side of the buttocks, per treatment session * have their pictures taken before and after each treatment session, and once more during the final visit

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCellulite
CountriesUnited States
CollaboratorsMerz North America, Inc.

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedJun 1, 2023
Enrollment StartJan 1, 2023
Primary CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.1 years ago

Interventions

Calcium Hydroxyapatitedrug

Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.